This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.本發明係關於人類纖維母細胞生長因子21(FGF21)之藥理學上有效及/或穩定之變體、包含FGF21變體之醫藥組合物及使用該等變體治療II型糖尿病、肥胖症、異常血脂症或代謝症候群或其任一組合之方法。